Last edition
News about "Cellenkos"
Cellenkos Receives US FDA IND Clearance for CK0802 Phase 1b/ 2a Trial in GVHD
The US Food and Drug Administration (FDA) clears Cellenkos Inc IND for CK0802, a first-in-class off-the-shelf Treg therapy, advancing to a phase 1b/2a trial in steroid-refractory Graft-Versus-Host Disease (GVHD).
Cellenkos | 06/05/2026 | By News Bureau
US FDA Grants Orphan Drug Designation to CK0804 Treg Therapy of Cellenkos
The US FDA has granted Orphan Drug Designation to Cellenkos’ CK0804, a first-in-class CXCR4hi Treg therapy for myelofibrosis. The investigational therapy is designed to home to the bone marrow and spleen, where it modulates inflammation through in-vivo expansion and IL-10 secretion.
Cellenkos | 07/01/2026 | By News Bureau | 134
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy